RxDoctor Payments Data

Tehreen Khan, MD

Cardiovascular Disease · Brandon, FLNPI 1619975141

Payments from drug & device makers

$553,933in general payments, 2019–2025

Across 505 payments — averaging $1096.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$352K
  • Boehringer Ingelheim International GmbH$124K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$63K
  • Merck$7K
  • Novo Nordisk AS$4K
  • Novartis$4K
  • plus $1K from 7 others

What the payments were for

  • Food & beverage$1,087100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$553,933 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$630,573
Medicare patients
1,637
Services billed
5,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban394$483,485
EntrestoSacubitril/Valsartan131$190,053
JardianceEmpagliflozin72$88,037
XareltoRivaroxaban78$87,396
FarxigaDapagliflozin Propanediol75$86,572
Metoprolol Succinate645$11,558
Repatha SureclickEvolocumab13$10,377
Atorvastatin Calcium298$2,909
ClopidogrelClopidogrel Bisulfate253$2,783
Ranolazine ErRanolazine26$2,434
Losartan Potassium243$2,316
Rosuvastatin Calcium154$2,282
Carvedilol228$2,128
Midodrine Hcl30$1,851
Amlodipine Besylate250$1,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$483,485394 claims
NovartisEntresto$3,500$190,053131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →